Evidence map›Paper›PMID 23941109›Full record

ArticleJournal of biomedical science2013

Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia.

Wen-Chi Yang, Wan-Chi Tsai, Pai-Mei Lin, Ming-Yu Yang, Yi-Chang Liu, Chao-Sung Chang, Wen-Hui Yu, Sheng-Fung Lin

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Frontiers in cell and developmental biology · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Wen-Chi YangDivision of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, No, 100 Tzyou 1st Road, 807 Kaohsiung, Taiwan. shlin@kmu.edu.tw.
Wan-Chi Tsai
Pai-Mei Lin
Ming-Yu Yang
Yi-Chang Liu
Chao-Sung Chang
Wen-Hui Yu
Sheng-Fung Lin
Kaohsiung Medical University · TWKaohsiung Medical University Chung-Ho Memorial Hospital · TWChang Gung University · TWI-Shou University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe relevance of recurrent molecular abnormalities in cytogenetically normal (CN) acute myeloid leukemia (AML) was recently acknowledged by the inclusion of molecular markers such as NPM1, FLT3, and CEBPA as a complement to cytogenetic information within both the World Health Organization and the European Leukemia Net classifications. Mitochondrial metabolism is different in cancer and normal cells. A novel cytosolic type 2-hydroxybutyrate dehydrogenase, BDH2, originally named DHRS6, plays a physiological role in the cytosolic utilization of ketone bodies, which can subsequently enter mitochondria and the tricarboxylic acid cycle. Moreover, BDH2 catalyzes the production of 2, 3-DHBA during enterobactin biosynthesis and participates in 24p3 (LCN2)-mediated iron transport and apoptosis.

resultsWe observed that BDH2 expression is an independent poor prognostic factor for CN-AML, with an anti-apoptotic role. Patients with high BDH2 expression have relatively shorter overall survival (P = 0.007) and a low complete response rate (P = 0.032). BDH2-knockdown (BDH2-KD) in THP1 and HL60 cells increased the apoptosis rate under reactive oxygen species stimulation. Decrease inducible survivin, a member of the inhibitors of apoptosis family, but not members of the Bcl-2 family, induced apoptosis via a caspase-3-independent pathway upon BDH2-KD.

conclusionsBDH2 is a novel independent poor prognostic marker for CN-AML, with the role of anti-apoptosis, through surviving.

Indexed as

Gene Expression Regulation, LeukemicAdultAgedAged, 80 and overApoptosisCell LineChinaFemaleGene Knockdown TechniquesHL-60 CellsHumansHydroxybutyrate DehydrogenaseInhibitor of Apoptosis ProteinsLeukemia, Myeloid, AcuteMaleMiddle AgedBDH2 protein, humanBIRC5 protein, humanHydroxybutyrate DehydrogenaseInhibitor of Apoptosis ProteinsNPM1 protein, humanNucleophosminSurvivin

Identifiers

PMID23941109
PMCPMC3844465
OpenAlexW2163919754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.